Table 3 Overall survival in patients with high-grade salivary gland cancers (n = 124)
Factors (Number) | Univariate model | Multivariate model #1 | Multivariate model #2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
Age (years) | 1.032 | 1.005–1.059 | 0.019 | 1.038 | 1.008–1.069 | 0.012 | 1.054 | 1.024–1.084 | < 0.001 |
Gender (Male/Female) (95/29) | 1.396 | 0.645–3.022 | 0.397 | ||||||
Primary site | |||||||||
Parotid gland (84) | 1 (Ref.) | ||||||||
Non-parotid gland (40) | 1.286 | 0.687–2.405 | 0.432 | ||||||
TNM categories | |||||||||
T3–4/T1–2 (60/64) | 1.785 | 0.955–3.336 | 0.069 | 0.807 | 0.405–1.609 | 0.542 | 0.964 | 0.505–1.839 | 0.912 |
N1–3/N0 (61/63) | 5.002 | 2.492–10.042 | < 0.001 | 9.263 | 4.025–21.317 | < 0.001 | 7.010 | 3.176–15.472 | < 0.001 |
M1/M0 (15/109) | 4.171 | 1.978–8.795 | < 0.001 | 4.716 | 2.148–10.357 | < 0.001 | |||
Pathological diagnosis | |||||||||
Salivary duct carcinoma (74) | 1 (Ref.) | ||||||||
Squamous cell carcinoma, primary (13) | 1.434 | 0.582–3.534 | 0.433 | ||||||
Adenoid cystic carcinoma, solid type (12) | 1.381 | 0.523–3.646 | 0.515 | ||||||
Mucoepidermoid carcinoma, high-grade (9) | 1.458 | 0.501–4.246 | 0.489 | ||||||
Adenocarcinoma, high-grade (6) | 0.370 | 0.050–2.752 | 0.332 | ||||||
Others* (10) | 2.059 | 0.707–5.999 | 0.186 | ||||||
Treatment modalities | |||||||||
Surgery (13) | 1 (Ref) | 1 (Ref.) | |||||||
Surgery + radiation (62) | 0.945 | 0.355–2.514 | 0.909 | 0.720 | 0.254–2.044 | 0.537 | |||
Surgery + radiation + chemotherapy (28) | 0.299 | 0.070–1.276 | 0.103 | 0.158 | 0.033–0.755 | 0.021 | |||
Others† (21) | 3.282 | 1.115–9.655 | 0.031 | 1.793 | 0.374–8.602 | 0.466 | |||